Cowen Reaffirms “Buy” Rating for Edwards Lifesciences (NYSE:EW)

Cowen restated their buy rating on shares of Edwards Lifesciences (NYSE:EW) in a research note issued to investors on Monday, February 4th.

A number of other brokerages have also issued reports on EW. Raymond James increased their price objective on Edwards Lifesciences from $160.00 to $175.00 and gave the stock an outperform rating in a report on Thursday, December 6th. Citigroup increased their price objective on Edwards Lifesciences from $118.00 to $119.00 and gave the company a sell rating in a research report on Wednesday, January 2nd. Morgan Stanley raised their price target on Edwards Lifesciences from $157.00 to $180.00 and gave the company an overweight rating in a research report on Friday, December 7th. Canaccord Genuity raised their price target on Edwards Lifesciences from $177.00 to $186.00 and gave the company a positive rating in a research report on Wednesday, January 16th. Finally, Stifel Nicolaus reiterated a positive rating on shares of Edwards Lifesciences in a research note on Thursday, December 6th. Two analysts have rated the stock with a sell rating, seven have issued a hold rating and thirteen have given a buy rating to the company’s stock. Edwards Lifesciences has an average rating of Buy and a consensus price target of $170.38.

EW traded up $4.42 during mid-day trading on Monday, hitting $173.71. 1,282,384 shares of the stock were exchanged, compared to its average volume of 1,032,615. The company has a current ratio of 2.61, a quick ratio of 1.92 and a debt-to-equity ratio of 0.19. The firm has a market cap of $35.84 billion, a price-to-earnings ratio of 36.96, a PEG ratio of 2.23 and a beta of 0.92. Edwards Lifesciences has a 1-year low of $123.00 and a 1-year high of $178.68.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Thursday, January 31st. The medical research company reported $1.17 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $1.17. The firm had revenue of $977.70 million for the quarter, compared to the consensus estimate of $973.72 million. Edwards Lifesciences had a return on equity of 31.09% and a net margin of 19.40%. During the same quarter last year, the business posted $0.94 EPS. On average, research analysts forecast that Edwards Lifesciences will post 5.21 earnings per share for the current year.

In related news, VP Huimin Wang sold 3,800 shares of the business’s stock in a transaction that occurred on Thursday, December 6th. The shares were sold at an average price of $155.87, for a total transaction of $592,306.00. Following the completion of the transaction, the vice president now owns 35,024 shares of the company’s stock, valued at $5,459,190.88. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Michael A. Mussallem sold 32,800 shares of the stock in a transaction that occurred on Friday, December 21st. The stock was sold at an average price of $146.03, for a total transaction of $4,789,784.00. Following the completion of the transaction, the chief executive officer now owns 75,926 shares in the company, valued at approximately $11,087,473.78. The disclosure for this sale can be found here. Over the last three months, insiders have sold 145,822 shares of company stock worth $23,041,781. Insiders own 1.84% of the company’s stock.

A number of institutional investors and hedge funds have recently modified their holdings of EW. BlackRock Inc. raised its position in Edwards Lifesciences by 7.4% in the 4th quarter. BlackRock Inc. now owns 16,431,419 shares of the medical research company’s stock worth $2,516,802,000 after purchasing an additional 1,128,082 shares during the last quarter. Oregon Public Employees Retirement Fund boosted its position in Edwards Lifesciences by 21,360.5% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 10,636,891 shares of the medical research company’s stock valued at $69,000 after buying an additional 10,587,326 shares in the last quarter. FMR LLC raised its stake in Edwards Lifesciences by 28.9% during the fourth quarter. FMR LLC now owns 7,576,820 shares of the medical research company’s stock worth $1,160,540,000 after buying an additional 1,700,199 shares during the last quarter. Jennison Associates LLC grew its holdings in shares of Edwards Lifesciences by 184.7% during the fourth quarter. Jennison Associates LLC now owns 4,112,133 shares of the medical research company’s stock valued at $629,855,000 after buying an additional 2,667,749 shares during the last quarter. Finally, Brown Advisory Inc. boosted its holdings in Edwards Lifesciences by 2.2% during the third quarter. Brown Advisory Inc. now owns 3,950,371 shares of the medical research company’s stock worth $687,760,000 after purchasing an additional 84,355 shares during the last quarter. 82.79% of the stock is owned by hedge funds and other institutional investors.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and related delivery systems for the nonsurgical replacement of heart valves.

Recommended Story: Marijuana Stocks

Analyst Recommendations for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply